Skip to search formSkip to main contentSkip to account menu

VEGFR-2 DNA Vaccine VXM01

Known as: VXM01 
An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
ABSTRACT VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression… 
2016
2016
AIM To investigate possible associations between VEGFR-2 and IL-8 gene SNPs and 1-year response to intravitreal ranibizumab for… 
2016
2016
Aim:The current therapeutic approaches have a limited effect on the dysregulated pulmonary vascular remodeling, which is… 
2016
2016
Aim:Nanobody is an antibody fragment consisting of a single monomeric variable antibody domain, which can be used for a variety… 
2015
2015
VEGFR-2 is expressed on tumor vasculature and a target for anti-angiogenic intervention. VXM01 is a first in kind orally applied… 
2013
2013
3090 Background: VXM01 is an orally available, bacterially transmitted DNA vaccine targeting VEGFR-2. Pre-clinically, VXM01… 
2012
2012
Dhakal H P, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky K‐E… 
2012
2012
BackgroundThe investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses… 
2011
2011
It is not well‐understood how low‐laser therapy affects the skin of the applied area. This study analyzes skin of the masseteric… 
Highly Cited
2006
Highly Cited
2006
BACKGROUND: Endothelial progenitor cells (EPCs) have been identified among hematopoietic tissue‐derived progenitor cells that are…